TOP TEN perturbations for Q00532 (Homo sapiens)

Organism: Homo sapiens
Gene: Q00532
Selected probe(set): 207766_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q00532 (207766_at) across 5339 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):2.6263266
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

systemic onset JIA study 4 / oligoarticular JIA study 3

Relative Expression (log2-ratio):2.304058
Number of Samples:3 / 12
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control oligoarticular JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with persistent oligoarthritis (oligoarticular JIA).

atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):2.2623081
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

systemic onset JIA study 5 / oligoarticular JIA study 2

Relative Expression (log2-ratio):2.2480526
Number of Samples:3 / 12
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control oligoarticular JIA study 2
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of persistent oligoarticular juvenile idiopathic arthritis (JIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 4 / polyarticular JIA study 6

Relative Expression (log2-ratio):2.184414
Number of Samples:3 / 14
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control polyarticular JIA study 6
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative polyarthritis (RF- polyarthritis/RF- polyarticular JIA).

memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)

Relative Expression (log2-ratio):-2.1589499
Number of Samples:6 / 6
Experimental memory B cell study 1 (CD27high)
CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.
Control memory B cell study 1 (undivided)
CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.

systemic onset JIA study 4 / juvenile enthesitis related arthritis study 2 (ERA)

Relative Expression (log2-ratio):2.1252556
Number of Samples:3 / 3
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control juvenile enthesitis related arthritis study 2 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA).

systemic onset JIA study 5 / polyarticular JIA study 4 (RF negative)

Relative Expression (log2-ratio):2.0913105
Number of Samples:3 / 17
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control polyarticular JIA study 4 (RF negative)
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of polyarticular juvenile idiopathic arthritis, rheumatoid factor negative (polyJIA, RF neg.). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 4 / normal PBMC sample

Relative Expression (log2-ratio):2.081791
Number of Samples:3 / 27
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 5 / normal PBMC sample

Relative Expression (log2-ratio):2.0531693
Number of Samples:3 / 27
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.